L-290-2023

Agreement ID
L-290-2023
Lead IC
NIAID
Exclusivity
Exclusive
External Party
ModeX Therapeutics, Inc.
Fiscal Year
2024
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-3828     Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants